Colorado designers reveal which home design trends are falling out of favor and what homeowners should consider instead for ...

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and ...

Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

This guide deconstructs the pathophysiology of UTIs, exploring the anatomical risks in women, and the efficacy of antibiotic ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the ...

The publication of this infographic was supported by AstraZeneca. This content is intended for US Healthcare Professionals only. This infographic presents three-year follow-up data from the TOPAZ-1 ...

Washington, United States—US health regulators have approved a new antibiotic to treat urinary tract infections, a problem affecting more than 100 million people around the world, mainly women, ...